




Sheet 1 of 3

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50164/015002
	Serial No.	10/517,639
	Applicant	Fong et al.
	Filing Date	June 28, 2005
	Group	1614
	IDS Filed	March 13, 2006

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication (or Issue) Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
MG	4,298,604	11-03-1981	Hammell	—	—	
	4,491,588	01-01-1985	Rosenburg et al.	—	—	
	4,569,935	02-11-1986	Rosenburg et al.	—	—	
	4,883,792	11-28-1989	Timmins et al.	—	—	
	4,942,162	07-17-1990	Rosenberg et al.	—	—	
	5,002,938	03-26-1991	Wang et al.	—	—	
	5,110,809	05-05-1992	Wang et al.	—	—	
	5,310,545	05-10-1994	Eisen	—	—	
	5,358,959	10-25-1994	Halperin et al.	—	—	
	5,407,663	04-18-1995	Eisen	—	—	
	5,432,176	07-11-1995	Walser	—	—	
	5,643,936	07-01-1997	Halperin et al.	—	—	
	5,994,341	11-30-1999	Hunter et al.	—	—	
	6,075,056	06-13-2000	Quigley, Jr. et al.	—	—	
	6,207,703	03-27-2001	Ponikau	—	—	
MG	2001/0031799	10-18-2001	Ponikau	—	—	
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
MG	ES 2064288	01-16-1995	Spain (with English translation)	—	—	
MG	WO 99/20271	04-29-1999	WIPO	—	—	

EXAMINER	/Michel Graffeo/	DATE CONSIDERED	05/26/2006
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			



Sheet 2 of 3

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50164/015002
		Serial No.	10/517,639
		Applicant	Fong et al.
		Filing Date	June 28, 2005
		Group	1614
		IDS Filed	March 13, 2006

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

(37 C.F.R. § 1.98(b))

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
MG	Baciewicz and Baciewicz, "Ketoconazole and Fluconazole Drug Interactions," <i>Arch. Intern. Med.</i> 153:1970-1976 (1993).
	Delbarre, "On the Possible Anti-Rheumatic Effects (Immuno-Effector?) of Imidazole Derivatives," <i>Biomedicine</i> 27:97-98 (1977).
	Faergemann, "Treatment of Sebopsoriasis with Itraconazole," <i>Mykosen</i> 28:612-618 (1985).
	Flannery et al., "Levamisole," <i>Lancet</i> 1:750-751 (1975).
	Fredriksson, "Treatment of Dermatomycoses with Topical Econazole Combined With a Steroid as Compared With a Conventional Oxichinoline-Steroid Combination," <i>Curr. Ther. Res.</i> 26:958-961 (1979).
	Hantschke and Reichenberger, "Doppelblinde, Randomisierte Vergleichende in Vivo Untersuchungen Zwischen den Antimykotika Clotrimazol, Tolnaftat und Naftifin"), <i>Mykosen</i> 23:657-668 (1980).
	Ludwig et al., "Steroid-Specific Effects of Ketoconazole on Corticosteroid Disposition: Unaltered Prednisolone Elimination," <i>DICP</i> 23:858-861 (1989).
	Maloley et al., "Severe Reversible Thrombocytopenia Resulting From Butoconazole Cream", <i>DICP</i> 24:143-144. 1990
	Otterness and Niblack, "Clotrimazole and Rheumatoid Arthritis," <i>Lancet</i> 1:148 (1976).
	Panayi, "Treating Rheumatoid Arthritis with Clotrimazole," <i>Nat. Med.</i> 1:977-978 (1995).
	Rosenberg et al., "Treatment of Psoriasis with Antimicrobial Agents," <i>Seminars in Dermatology</i> 4:307-311 (1985).
	Schuermans, "Levamisole in Rheumatoid Arthritis," <i>Lancet</i> 1:111 (1975).
	Smith et al., "Phospholipid Metabolism in Polymorphonuclear Leukocytes From Rheumatoid Arthritis Patients: Effects of Non-Steroidal Anti-Inflammatory Agents and Clotrimazole," <i>Int J. Immunopharmacol</i> 11:45-55 (1989).
	van der Vleuten and van der Kerkhof, "Management of Scalp Psoriasis: Guidelines for Corticosteroid Use in Combination Treatment," <i>Drugs</i> 61:1593-1598 (2001).
	Wojtulewski et al., "Clotrimazole in Rheumatoid Arthritis," <i>Ann. Rheum. Dis.</i> 39:469-472 (1980).
	Wyburn-Mason, "Clotrimazole and Rheumatoid Arthritis," <i>Lancet</i> 1:489 (1976).
	Yamashita et al., "Lack of Pharmacokinetic and Pharmacodynamic Interactions Between Ketoconazole and Prednisolone," <i>Clin. Pharmacol. Ther.</i> 49:558-570 (1991).
MG	Zürcher et al., "Impact of Ketoconazole on the Metabolism of Prednisolone," <i>Clin. Pharmacol. Ther.</i> 45:366-372

EXAMINER /Michel Graffeo/	DATE CONSIDERED 05/26/2006
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

Sheet 3 of 3SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

(37 C.F.R. § 1.98(b))

Attorney Docket No.

50164/015002

Serial No.

10/517,639

Applicant

Fong et al.

Filing Date

June 28, 2005

Group

1614

IDS Filed

March 13, 2006

(1989).

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

~~PCT International Preliminary Examination Report (PCT/US03/17586); 3 pages.~~~~PCT International Search Report (PCT/US03/17586) (1 page), and cited document U.S. Patent No. 5,944,341
(Hunter et al.) (page 1).~~

EXAMINER

/Michel Graffeo/

DATE CONSIDERED

05/26/2006

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

Ⓢ Examiner has not considered these documents. Documents of this type require a publication date.